Navigation Links
BioCis Pharma Starts Phase IIa Trial in Psoriasis
Date:3/12/2009

TURKU, Finland, March 12 /PRNewswire/ -- BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, announced that it has begun a new Phase IIa clinical testing of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. The double-blind, vehicle-controlled study is designed to evaluate the tolerability, pharmacokinetics, and efficacy of the topical product in a total of 18 subjects with mild to moderate plaque psoriasis. The subjects will apply ProtoCure(TM) emulsion cream up to four weeks to the skin areas affected by the disease.

"With the commencement of this clinical trial we expand our clinical activities to a new dermatological indication," says Lasse Leino, CEO of BioCis Pharma. "Together with the ongoing phase IIa clinical trial in patients with mild to moderate atopic dermatitis, this first study in psoriasis will quickly enable us to obtain data to support our full-scale phase II clinical development program of ProtoCure(TM) emulsion cream in chronic skin inflammation. We expect to get results from both studies by third quarter of 2009."

Psoriasis is an immune-mediated chronic inflammatory disease characterized by local lesions on the skin. It affects about 2 to 3 per cent of the general population in the Western countries. Psoriasis may significantly impair the life quality of the affected subjects, and it may lead to psoriatic arthritis, an inflammatory disease affecting the joints. Existing treatments often have undesirable side effects and do not always meet the needs of patients.

BioCis Pharma Ltd is an innovative drug development company with a business idea to develop drug therapies based on a novel, patented therapeutic principle. BioCis Pharma is targeting unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The company's main investors are Karolinska Develo
'/>"/>

SOURCE BioCis Pharma Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
2. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results
3. Advance Nanotechs Owlstone Announces First Pharmaceutical Industry Order
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
5. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
6. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
7. Pharmaxis Appoints French Distributor for Aridol(TM)
8. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
9. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
10. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
11. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , ... July 29, 2015 , ... ... today announced its GHS Label Guide . To align chemical container labeling ... this guide includes explanations of label components, an example of an accurate label, ...
(Date:7/29/2015)... , July 29, 2015  Pfenex Inc. (NYSE MKT: ... results will be released on Thursday, August 13, 2015, ... Time, Pfenex management will host a conference call to ... A press release outlining the financial results and business ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - RepliCel Life Sciences ... regenerative medicine company, is pleased to announce that the ... (RCI-02) have been locked.  Prototypes for industrial and ... for an application for CE mark clearance to ... in 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences ... recruitment services. The core expertise of PRC Clinical is focused on Clinical Trial ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... and power solutions giant Johnson Controls, Inc. ... the creation an Executive Operating Committee. , ,Steve Roell, ... the EOC, a committee comprised of senior leaders. An ... vice president and chief financial officer from 1991 to ...
... Editor's note: This is the first of a two-part opinion piece on ... adison, Wis. - There has been a great deal ... want to save you the trouble of reading all this confusing information, ... you my opinion along with permission to repeat it at cocktail parties. ...
... DVD technology is aging rapidly and innovative competitors are ... As this evolution unfolds, one company has already begun ... DVD. , , Sony Media Software , a provider ... the release of a tool for authoring new high-capacity, ...
Cached Biology Technology:Anti-ethanol arguments are easily debunked 2Anti-ethanol arguments are easily debunked 3Sony releases tool for Blu-ray disc production 2
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting ... the addition of two new team members. ... David Raviv will act as head of strategic ... to providing the most secure solutions for the enterprise market. ... 7 Technologies, a provider of security and management products, which ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... that causes plaque buildup in Alzheimer,s disease is the focus ... Georgia Health Sciences University graduate student. In Alzheimer,s, the ... eliminated by the body,s natural defenses, nestling between the neurons ... gets there could be targets for a new vaccine. ...
... Sept. 26, 2011 -A compound tested by UT Southwestern Medical ... that killed an estimated 30 million people in the worldwide ... by increasing the levels of a human antiviral protein - ... the flu, a virus that tends to mutate into strains ...
... Scientists have for the first time discovered sixteen new sections ... opening up the possibility for better prevention as well ... 175 scientists from 126 centres in Europe, the USA and ... human lung. Their discovery sheds new light on the ...
Cached Biology News:Award-winning research points toward Alzheimer’s vaccine 2Compound kills highly contagious flu strain by activating antiviral protein 2New discoveries in genetics of lung health 2
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
... polyclonal to MKK6 (phospho S207) ( ... Antigen: Synthetic ... the phosphorylation site of Serine 207 ... Entrez Gene ID: 5608 ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Biology Products: